US008440402B2

(12) **United States Patent**
Mass

(10) **Patent No.: US 8,440,402 B2**
(45) **Date of Patent: *May 14, 2013**

(54) **GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO A HER2 ANTIBODY CANCER THERAPY**

(75) Inventor: **Robert D. Mass**, Mill Valley, CA (US)

(73) Assignee: **Genentech, Inc.**, South San Francisco, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/323,322**

(22) Filed: **Dec. 12, 2011**

(65) **Prior Publication Data**

US 2012/0093838 A1 Apr. 19, 2012

Related U.S. Application Data

(63) Continuation of application No. 11/690,304, filed on Mar. 23, 2007, now Pat. No. 8,076,066, which is a continuation of application No. 09/863,101, filed on May 18, 2001, now abandoned.

(60) Provisional application No. 60/205,754, filed on May 19, 2000.

(51) **Int. Cl.**
C12Q 1/68 (2006.01)
G01N 33/574 (2006.01)

(52) **U.S. Cl.**
USPC **435/6.1**; 435/7.23

(58) **Field of Classification Search** ..... None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,753,894	A	6/1988	Frankel
4,935,341	A	6/1990	Bargmann
4,943,533	A	7/1990	Mendelsohn
4,968,603	A	11/1990	Slamon
4,975,278	A	12/1990	Senter
5,169,774	A	12/1992	Frankel
5,183,884	A	2/1993	Kraus
5,288,477	A	2/1994	Bacus
5,359,046	A	10/1994	Capon
5,367,060	A	11/1994	Vandlen
5,401,638	A	3/1995	Carney
5,464,751	A	11/1995	Greene
5,480,968	A	1/1996	Kraus
5,514,554	A	5/1996	Bacus
5,571,894	A	11/1996	Wels
5,578,482	A	11/1996	Lippman
5,587,458	A	12/1996	King
5,604,107	A	2/1997	Carney
5,641,869	A	6/1997	Vandlen
5,663,144	A	9/1997	Greene
5,677,165	A	10/1997	de Boer
5,677,171	A	10/1997	Hudziak
5,705,157	A	1/1998	Greene
5,720,937	A	2/1998	Hudziak
5,720,954	A	2/1998	Hudziak
5,725,856	A	3/1998	Hudziak
5,726,023	A	3/1998	Cheever
5,728,687	A	3/1998	Bissery
5,736,137	A	4/1998	Anderson
5,747,261	A	5/1998	King
5,770,195	A	6/1998	Hudziak
5,772,997	A	6/1998	Hudziak
5,776,427	A	7/1998	Thorpe
5,783,186	A	7/1998	Arakawa
5,783,404	A	7/1998	Koski
5,801,005	A	9/1998	Cheever
5,804,396	A	9/1998	Plowman
5,821,337	A	10/1998	Carter
5,824,311	A	10/1998	Greene
8,824,311		10/1998	Greene
5,834,229	A	11/1998	Vandlen
5,837,243	A	11/1998	Deo
5,837,523	A	11/1998	Greene
5,840,525	A	11/1998	Vandlen
5,846,538	A	12/1998	Cheever
5,846,749	A	12/1998	Slamon
5,856,089	A	1/1999	Wang
5,856,110	A	1/1999	Vandlen
5,859,206	A	1/1999	Vandlen
5,869,445	A	2/1999	Cheever
5,876,712	A	3/1999	Cheever
5,877,305	A	3/1999	Huston
5,908,835	A	6/1999	Bissery
5,910,486	A	6/1999	Curiel
5,922,845	A	7/1999	Deo
5,925,519	A	7/1999	Jensen
5,939,531	A	8/1999	Wels
5,968,511	A	10/1999	Akita
5,977,322	A	11/1999	Marks

(Continued)

FOREIGN PATENT DOCUMENTS

EP	412116	4/1989
EP	332865	9/1989

(Continued)

OTHER PUBLICATIONS

Sneige et al, 2000 Annual Meeting United States and Canadian Academy of Pathology, Mar. 25-31, 2000, abstract #258 on p. 47A.*

(Continued)

Primary Examiner — Laura B Goddard

(74) *Attorney, Agent, or Firm* — Diane Marschang; Ginger R. Dreger; Arnold & Porter LLP

(57) **ABSTRACT**

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing HER2, as determined by a gene amplification assay, with a HER2 antibody. Such method comprises administering a cancer-treating dose of the HER2 antibody, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells her2 has been found to be amplified e.g., by fluorescent in situ hybridization.

6 Claims, No Drawings